Heart Failure With Mid Range Ejection Fraction

Heart failure with mid-range ejection fraction (HFmrEF) represents a unique and often misunderstood category within the broader spectrum of heart failure. That's why it's a condition where the heart muscle's ability to contract and pump blood is somewhat impaired, falling in between the more clearly defined categories of heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Understanding HFmrEF is crucial for accurate diagnosis, effective management, and ultimately, improving patient outcomes.

Understanding Ejection Fraction

Before diving into the specifics of HFmrEF, let's clarify the concept of ejection fraction (EF). That's why eF is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction. The left ventricle is the heart's main pumping chamber, responsible for sending oxygen-rich blood to the body.

• Normal EF: Typically between 55% and 70%. Basically, with each heartbeat, the left ventricle ejects 55% to 70% of the blood it contains.
• HFpEF (Heart Failure with Preserved Ejection Fraction): EF is usually 50% or higher. In this case, the heart can contract normally, but it's often stiff or thick, preventing it from filling properly with blood.
• HFrEF (Heart Failure with Reduced Ejection Fraction): EF is 40% or lower. Here, the heart muscle is weakened and cannot contract effectively, leading to a reduced amount of blood being pumped out.
• HFmrEF (Heart Failure with Mid-Range Ejection Fraction): EF falls between 41% and 49%. This is the "gray area" where the heart's pumping ability is mildly impaired.

The Nuances of HFmrEF

HFmrEF is not simply a midpoint between HFrEF and HFpEF. It's increasingly recognized as a distinct entity with its own characteristics, underlying mechanisms, and treatment considerations. Here's a closer look:

Diagnostic Criteria

The diagnosis of HFmrEF typically involves the following:

• Symptoms of Heart Failure: These can include shortness of breath (dyspnea), fatigue, swelling in the ankles, legs, and abdomen (edema), and difficulty breathing when lying down (orthopnea).
• Ejection Fraction Measurement: An echocardiogram, a non-invasive ultrasound of the heart, is used to measure the EF. An EF between 41% and 49% is a key criterion for HFmrEF.
• Elevated Levels of Natriuretic Peptides: These are hormones released by the heart in response to stress. Elevated levels of B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) support the diagnosis of heart failure.

it helps to note that relying solely on EF to classify heart failure can be misleading. Many patients with HFmrEF have other underlying conditions that contribute to their symptoms.

Underlying Causes and Risk Factors

The causes of HFmrEF can be varied and often overlap with those of HFrEF and HFpEF. Some common factors include:

• Coronary Artery Disease (CAD): Blockages in the arteries that supply blood to the heart muscle can weaken the heart and lead to HFmrEF.
• Hypertension (High Blood Pressure): Long-standing high blood pressure can strain the heart, causing it to thicken and stiffen.
• Diabetes: Diabetes can damage the heart muscle and blood vessels, increasing the risk of heart failure.
• Valvular Heart Disease: Problems with the heart valves, such as stenosis (narrowing) or regurgitation (leakage), can force the heart to work harder and lead to heart failure.
• Cardiomyopathy: This refers to diseases of the heart muscle itself. Different types of cardiomyopathy, such as dilated cardiomyopathy or hypertrophic cardiomyopathy, can contribute to HFmrEF.
• Atrial Fibrillation: This irregular heart rhythm can weaken the heart over time.
• Obesity: Obesity is a significant risk factor for many cardiovascular diseases, including heart failure.
• Age: The risk of heart failure increases with age.

Pathophysiology

The pathophysiology of HFmrEF, or how the disease develops, is complex and not fully understood. It's likely a combination of factors that impair both the heart's ability to contract (systolic function) and its ability to relax and fill with blood (diastolic function). Some potential mechanisms include:

• Myocardial Remodeling: Changes in the structure and function of the heart muscle, such as enlargement (hypertrophy) and scarring (fibrosis), can impair both systolic and diastolic function.
• Impaired Calcium Handling: Calcium has a big impact in muscle contraction. Problems with how the heart muscle handles calcium can lead to reduced contractility.
• Endothelial Dysfunction: The endothelium is the inner lining of blood vessels. Dysfunction of the endothelium can contribute to inflammation and impaired blood flow to the heart.
• Inflammation: Chronic inflammation can damage the heart muscle and contribute to heart failure.

Challenges in Diagnosis and Management

HFmrEF presents several challenges for clinicians:

• Heterogeneity: Patients with HFmrEF are a diverse group with varying underlying causes and clinical presentations. This makes it difficult to develop a one-size-fits-all treatment approach.
• Lack of Specific Guidelines: Unlike HFrEF and HFpEF, there are no specific, evidence-based guidelines for the management of HFmrEF.
• Fluctuating EF: Some patients with HFmrEF may have an EF that fluctuates over time, moving into the HFrEF or HFpEF range. This can make it difficult to classify and treat the condition.
• Misdiagnosis: HFmrEF can be misdiagnosed as either HFrEF or HFpEF, leading to inappropriate treatment.

Management Strategies for HFmrEF

Given the lack of specific guidelines, the management of HFmrEF typically involves a combination of approaches used for HFrEF and HFpEF, suited to the individual patient's needs.

Lifestyle Modifications

Lifestyle changes are a cornerstone of heart failure management, regardless of the EF. These include:

• Dietary Changes: A heart-healthy diet that is low in sodium, saturated and trans fats, and cholesterol is essential. Limiting fluid intake may also be necessary for some patients.
• Regular Exercise: Moderate-intensity aerobic exercise, such as walking, cycling, or swimming, can improve cardiovascular function and quality of life.
• Weight Management: Maintaining a healthy weight can reduce the strain on the heart.
• Smoking Cessation: Smoking damages the heart and blood vessels and should be avoided.
• Alcohol Moderation: Excessive alcohol consumption can weaken the heart muscle.
• Stress Management: Chronic stress can contribute to heart disease. Techniques such as yoga, meditation, and deep breathing can help manage stress.

Medications

Medications play a vital role in managing the symptoms and progression of HFmrEF. The choice of medications depends on the individual patient's symptoms, underlying conditions, and tolerance. Some commonly used medications include:

Want to learn more? We recommend why do we only see part of the moon and why are diamonds so hard for further reading.

• Diuretics: These medications help the body eliminate excess fluid, reducing swelling and shortness of breath. Common diuretics include furosemide (Lasix) and hydrochlorothiazide.
• ACE Inhibitors or ARBs: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) help relax blood vessels and lower blood pressure. They are often used in HFrEF and may be beneficial in some patients with HFmrEF.
• Beta-Blockers: These medications slow the heart rate and lower blood pressure. They are also commonly used in HFrEF and may be considered in HFmrEF, particularly if the patient has a history of heart attack or high blood pressure.
• Mineralocorticoid Receptor Antagonists (MRAs): These medications, such as spironolactone and eplerenone, block the effects of aldosterone, a hormone that can contribute to sodium and water retention. They are often used in HFrEF and may be beneficial in HFmrEF, especially in patients with persistent symptoms despite other treatments.
• ARNI (Angiotensin Receptor-Neprilysin Inhibitor): ARNI, such as sacubitril/valsartan, combines an ARB with a neprilysin inhibitor. It has been shown to be more effective than ACE inhibitors in HFrEF and may be considered in HFmrEF, particularly if the patient's EF is closer to the HFrEF range or if they have persistent symptoms.
• SGLT2 Inhibitors: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, were originally developed for diabetes but have been shown to have benefits in heart failure, regardless of diabetes status. They are now recommended for HFrEF and are being increasingly studied in HFmrEF.
• Digoxin: This medication can help strengthen the heart's contractions and control heart rate. It is sometimes used in HFmrEF to manage symptoms.

It's crucial for patients to take their medications as prescribed and to discuss any side effects or concerns with their doctor.

Device Therapy

In some cases, device therapy may be considered for patients with HFmrEF. These devices can help improve heart function and reduce the risk of sudden cardiac death.

• Implantable Cardioverter-Defibrillator (ICD): An ICD is a device that is implanted in the chest to monitor the heart rhythm. If it detects a dangerous arrhythmia, it can deliver an electrical shock to restore a normal rhythm. ICDs are typically used in patients with HFrEF who are at high risk of sudden cardiac death. Their role in HFmrEF is less clear, but they may be considered in select patients with specific risk factors.
• Cardiac Resynchronization Therapy (CRT): CRT is a device that is implanted in the chest to help coordinate the contractions of the left and right ventricles. It is typically used in patients with HFrEF who have a wide QRS complex on their electrocardiogram (ECG), indicating a delay in electrical conduction in the heart. The role of CRT in HFmrEF is also less clear, but it may be considered in select patients with a wide QRS complex and significant symptoms.

Managing Comorbidities

Many patients with HFmrEF have other underlying conditions, or comorbidities, that can worsen their heart failure symptoms and prognosis. It's essential to manage these comorbidities effectively.

• Coronary Artery Disease: If CAD is present, treatment may involve medications to lower cholesterol and blood pressure, as well as procedures such as angioplasty or bypass surgery to improve blood flow to the heart.
• Hypertension: Controlling high blood pressure is crucial to reduce the strain on the heart. This may involve lifestyle changes and medications.
• Diabetes: Managing blood sugar levels is essential to prevent further damage to the heart and blood vessels. This may involve lifestyle changes, medications, and regular monitoring of blood sugar.
• Atrial Fibrillation: Managing atrial fibrillation may involve medications to control heart rate and rhythm, as well as procedures such as cardioversion or ablation to restore a normal heart rhythm.
• Sleep Apnea: Sleep apnea, a condition in which breathing repeatedly stops and starts during sleep, can worsen heart failure. Treatment may involve continuous positive airway pressure (CPAP) therapy.
• Anemia: Anemia, a condition in which the blood does not have enough red blood cells, can worsen heart failure symptoms. Treatment may involve iron supplementation or other therapies to increase red blood cell production.

Regular Monitoring

Regular monitoring is essential for patients with HFmrEF to assess their response to treatment and to detect any changes in their condition. This may involve:

• Regular Checkups: Regular visits to the doctor to monitor symptoms, weight, blood pressure, and heart rate.
• Echocardiograms: Repeat echocardiograms to monitor the EF and heart function.
• Blood Tests: Regular blood tests to monitor kidney function, electrolyte levels, and natriuretic peptide levels.
• ECGs: Regular ECGs to monitor heart rhythm.

Emerging Therapies and Research

Research into HFmrEF is ongoing, and new therapies are being developed. Some promising areas of research include:

• Targeted Therapies: Developing therapies that specifically target the underlying mechanisms of HFmrEF, such as myocardial remodeling and impaired calcium handling.
• Biomarkers: Identifying biomarkers that can help predict prognosis and response to treatment in HFmrEF.
• Personalized Medicine: Tailoring treatment to the individual patient based on their specific characteristics and underlying conditions.

Conclusion

Heart failure with mid-range ejection fraction (HFmrEF) is a complex and challenging condition that requires a comprehensive and individualized approach to management. Still, while it shares features with both HFrEF and HFpEF, it's increasingly recognized as a distinct entity with its own characteristics and treatment considerations. By understanding the nuances of HFmrEF, clinicians can provide more effective care and improve outcomes for patients with this condition. Lifestyle modifications, medications, device therapy, and management of comorbidities all play a crucial role in managing HFmrEF. Ongoing research is essential to further our understanding of this condition and to develop new and more effective therapies.